HRP20240052T1 - Kombinirana terapija protiv raka - Google Patents
Kombinirana terapija protiv raka Download PDFInfo
- Publication number
- HRP20240052T1 HRP20240052T1 HRP20240052TT HRP20240052T HRP20240052T1 HR P20240052 T1 HRP20240052 T1 HR P20240052T1 HR P20240052T T HRP20240052T T HR P20240052TT HR P20240052 T HRP20240052 T HR P20240052T HR P20240052 T1 HRP20240052 T1 HR P20240052T1
- Authority
- HR
- Croatia
- Prior art keywords
- adjuvant
- immunotherapeutic composition
- use according
- montanide isa
- combination therapy
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 2
- 201000011510 cancer Diseases 0.000 title claims 2
- 238000002648 combination therapy Methods 0.000 title 1
- 239000002671 adjuvant Substances 0.000 claims 5
- 230000001024 immunotherapeutic effect Effects 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 108020000946 Bacterial DNA Proteins 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940124669 imidazoquinoline Drugs 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (4)
1. Imunoterapeutski sastav za upotrebu u postupku za prevenciju ili liječenje raka kod subjekta, postupak obuhvaća primjenu na navedenom subjektu:
(i) navedene imunoterapeutske sastave, koji sadrže peptid sekvence DTLLKALLEIASCLEKALQVF (SEQ ID NO: 3) i peptid sekvence FMTIVHLLNAFTVTVPKDL (SEQ ID NO: 32); i
(ii) imunomodulatorno sredstvo koje je inhibitorno antitijelo koje se veže za PD1.
2. Imunoterapeutski sastav za upotrebu prema patentnom zahtjevu 1, pri čemu je anti-PD1 antitijelo pembrolizumab ili nivolumab.
3. Imunoterapeutski sastav za upotrebu prema bilo kojem od prethodnih patentnih zahtjeva, koji uključuje pomoćno sredstvo ili nosač, po potrebi pri čemu je navedeno pomoćno sredstvo izabrano između bakterijskog DNK pomoćnog sredstva, ulja/površinski aktivnog pomoćnog sredstva, virusnog dsRNK pomoćnog sredstva, imidazohinolina i GM-CSF-a.
4. Imunoterapeutski sastav za upotrebu prema patentnom zahtjevu 3 pri čemu je navedeno pomoćno sredstvo Montanide ISA pomoćno sredstvo, po potrebi izabrano između Montanide ISA 51 ili Montanide ISA 720.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1603805.1A GB201603805D0 (en) | 2016-03-04 | 2016-03-04 | Combination |
| GBGB1610018.2A GB201610018D0 (en) | 2016-06-08 | 2016-06-08 | Combination |
| EP17709038.8A EP3423087B1 (en) | 2016-03-04 | 2017-03-03 | Combination therapy against cancer |
| PCT/EP2017/055093 WO2017149150A1 (en) | 2016-03-04 | 2017-03-03 | Combination therapy against cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240052T1 true HRP20240052T1 (hr) | 2024-03-29 |
Family
ID=58231605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240052TT HRP20240052T1 (hr) | 2016-03-04 | 2017-03-03 | Kombinirana terapija protiv raka |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20190343940A1 (hr) |
| EP (2) | EP3423087B1 (hr) |
| JP (3) | JP2019507180A (hr) |
| DK (1) | DK3423087T3 (hr) |
| ES (1) | ES2965009T3 (hr) |
| FI (1) | FI3423087T3 (hr) |
| HR (1) | HRP20240052T1 (hr) |
| HU (1) | HUE064857T2 (hr) |
| LT (1) | LT3423087T (hr) |
| PL (1) | PL3423087T3 (hr) |
| PT (1) | PT3423087T (hr) |
| SI (1) | SI3423087T1 (hr) |
| WO (1) | WO2017149150A1 (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6900323B2 (ja) | 2015-05-29 | 2021-07-07 | アジェナス インコーポレイテッド | 抗ｃｔｌａ−４抗体およびその使用方法 |
| KR20180069903A (ko) | 2015-11-02 | 2018-06-25 | 파이브 프라임 테라퓨틱스, 인크. | Cd80 세포외 도메인 폴리펩타이드 및 이들의 암 치료에서의 용도 |
| CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| KR102504605B1 (ko) | 2016-12-07 | 2023-03-02 | 아게누스 인코포레이티드 | 항-ctla-4 항체 및 이의 사용 방법 |
| WO2018201014A1 (en) | 2017-04-28 | 2018-11-01 | Five Prime Therapeutics, Inc. | Methods of treatment with cd80 extracellular domain polypeptides |
| JP7437301B2 (ja) | 2017-08-25 | 2024-02-22 | ファイヴ プライム セラピューティクス インク | Ｂ７－ｈ４抗体及びその使用方法 |
| WO2019102265A1 (en) * | 2017-11-23 | 2019-05-31 | Theraphage Inc. | Peptide displaying bacteriophage nanoparticles and related compositions and methods |
| CN111372656A (zh) * | 2017-11-24 | 2020-07-03 | Io生物技术公司 | 抗体依赖性细胞介导的细胞毒性(adcc)的增强 |
| CN111971308A (zh) | 2018-03-02 | 2020-11-20 | 戊瑞治疗有限公司 | B7-h4抗体及其使用方法 |
| KR102653960B1 (ko) * | 2020-07-23 | 2024-04-03 | 의료법인 성광의료재단 | 암 치료를 위한 면역체크포인트 억제제의 병용 요법 |
| EP4301358A2 (en) | 2021-03-05 | 2024-01-10 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
| EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
| GB202103673D0 (en) * | 2021-03-17 | 2021-04-28 | Io Biotech Aps | Combination therapy for cancer |
| EP4340948A1 (en) * | 2021-05-17 | 2024-03-27 | Wisconsin Alumni Research Foundation (WARF) | Synthetic protein for inducing immune tolerance |
| WO2023159197A1 (en) * | 2022-02-18 | 2023-08-24 | Modernatx, Inc. | Mrnas encoding checkpoint cancer vaccines and uses thereof |
| WO2023161350A1 (en) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US58767A (en) | 1866-10-16 | John brougjbton | ||
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US20100055111A1 (en) * | 2007-02-14 | 2010-03-04 | Med. College Of Georgia Research Institute, Inc. | Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells |
| CA2721150C (en) | 2008-04-17 | 2017-09-26 | Herlev Hospital | Indoleamine 2,3-dioxygenase based immunotherapy |
| CN103917243B (zh) * | 2011-10-17 | 2021-05-11 | Io生物技术公司 | 基于pd-l1的免疫疗法 |
| GB201311475D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Polypeptides |
| SG10201806297VA (en) * | 2014-02-04 | 2018-08-30 | Incyte Corp | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer |
| JP6652557B2 (ja) * | 2014-05-30 | 2020-02-26 | ヴェンタナ メディカル システムズ， インク． | Ｐｄ−ｌ１について染色された腫瘍組織の改善されたスコア化のための多重アッセイ |
-
2017
- 2017-03-03 HR HRP20240052TT patent/HRP20240052T1/hr unknown
- 2017-03-03 PT PT177090388T patent/PT3423087T/pt unknown
- 2017-03-03 PL PL17709038.8T patent/PL3423087T3/pl unknown
- 2017-03-03 LT LTEPPCT/EP2017/055093T patent/LT3423087T/lt unknown
- 2017-03-03 EP EP17709038.8A patent/EP3423087B1/en active Active
- 2017-03-03 WO PCT/EP2017/055093 patent/WO2017149150A1/en active Application Filing
- 2017-03-03 US US16/081,778 patent/US20190343940A1/en not_active Abandoned
- 2017-03-03 EP EP23202447.1A patent/EP4316517A3/en active Pending
- 2017-03-03 HU HUE17709038A patent/HUE064857T2/hu unknown
- 2017-03-03 DK DK17709038.8T patent/DK3423087T3/da active
- 2017-03-03 JP JP2018546596A patent/JP2019507180A/ja active Pending
- 2017-03-03 SI SI201731444T patent/SI3423087T1/sl unknown
- 2017-03-03 FI FIEP17709038.8T patent/FI3423087T3/fi active
- 2017-03-03 ES ES17709038T patent/ES2965009T3/es active Active
-
2021
- 2021-09-07 US US17/468,263 patent/US20220257741A1/en active Pending
-
2022
- 2022-02-25 JP JP2022027569A patent/JP7417645B2/ja active Active
-
2024
- 2024-01-05 JP JP2024000506A patent/JP2024045180A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3423087B1 (en) | 2023-11-15 |
| EP4316517A3 (en) | 2024-05-29 |
| JP2024045180A (ja) | 2024-04-02 |
| US20190343940A1 (en) | 2019-11-14 |
| DK3423087T3 (da) | 2023-12-18 |
| JP2022068348A (ja) | 2022-05-09 |
| FI3423087T3 (fi) | 2023-12-15 |
| PT3423087T (pt) | 2023-12-28 |
| EP4316517A2 (en) | 2024-02-07 |
| US20220257741A1 (en) | 2022-08-18 |
| WO2017149150A1 (en) | 2017-09-08 |
| HUE064857T2 (hu) | 2024-04-28 |
| EP3423087A1 (en) | 2019-01-09 |
| JP7417645B2 (ja) | 2024-01-18 |
| PL3423087T3 (pl) | 2024-05-20 |
| JP2019507180A (ja) | 2019-03-14 |
| SI3423087T1 (sl) | 2024-03-29 |
| ES2965009T3 (es) | 2024-04-10 |
| LT3423087T (lt) | 2024-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240052T1 (hr) | Kombinirana terapija protiv raka | |
| IL268135A (en) | Eyepiece for virtual, augmented or mixed reality systems | |
| MX2023003461A (es) | Tratamiento de infeccion por clostridium difficile. | |
| WO2017191258A9 (en) | Influenza mrna vaccines | |
| CL2021001541A1 (es) | Un complejo novedoso que comprende un péptido penetrante de células, una carga y un agonista de péptido de tlr para tratamiento de cáncer colorrectal (divisional de la solicitud no. 201900694) | |
| PH12018501962A1 (en) | Stablizied soluble pre-fusion rsv f proteins | |
| CO2017012562A2 (es) | Vectores virales adenoasociados que codifican para la enzima iduronato-2-sulfatasa | |
| TR201901445T4 (tr) | Il2rbeta/yaygın gamma zinciri antikorları. | |
| BR112017010088A2 (pt) | polinucleotídeo modulatório, pré-micro-rna artificial, vírus recombinante de aav, composição compreendendo o plasmídeo ou vetor, kit compreendendo o referido plasmídeo ou vetor e uso do mesmo | |
| WO2015181356A8 (en) | Vaccine composition against streptococcus suis infection | |
| BR112019017403A2 (pt) | composições e métodos para o tratamento de câncer | |
| WO2016183366A3 (en) | Compositions and methods for silencing expression of hepatitis d virus rna | |
| PH12018502332A1 (en) | Stabilized pre-fusion rsv f proteins | |
| PH12020500569A1 (en) | Influenza virus vaccines and uses thereof | |
| PH12019550069A1 (en) | Nucleoside phosphate compound and preparation method and use thereof | |
| CL2022000531A1 (es) | Composiciones y métodos para el tratamiento de infecciones virales. | |
| BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
| MX2020008125A (es) | Composiciones que comprenden berberina. | |
| CL2018002793A1 (es) | Terapia de cáncer con un virus oncolítico combinado con un inhibidor de puntos de control | |
| WO2016038521A8 (en) | Pharmaceutical compositions of liraglutide | |
| MX2021005345A (es) | Composiciones y metodos. | |
| MX2019015007A (es) | Composiciones inmunogénicas que comprenden los polipéptidos derivados de la leucocidina de staphylococcus aureus luka y lukb. | |
| MX2022016066A (es) | Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. | |
| CL2016001977A1 (es) | Composición que comprende igm derivada de plasma y su uso para el tratamiento o prevención de afecciones inmunitarias. | |
| CO6362049A2 (es) | Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo |